Department of Pharmacy, University of Washington, Seattle, WA, USA.
Department of Pharmacy, University of Washington, Seattle, WA, USA.
Value Health. 2020 Dec;23(12):1523-1533. doi: 10.1016/j.jval.2020.08.2092. Epub 2020 Oct 16.
The quality-adjusted life-year (QALY) has been long debated, but alternative estimation approaches have not been comprehensively evaluated. Our objective was to identify alternatives, characterize them by implementation feasibility, and evaluate the impact of implementing feasible options in cost-effectiveness models developed for the Institute for Clinical and Economic Review reports.
We conducted a literature review combining keywords relating to QALYs, methodology alternatives, and cost-effectiveness in PubMed, EconLit, Web of Science, and MEDLINE. Articles that discussed alternatives to the conventional QALY were included. Alternatives were characterized by type, data availability, calculation burden, and overall implementation feasibility. The subset of feasible alternatives, that is, sufficient data and methodology compatible with incorporation into common modeling approaches, were evaluated according to impact on incremental QALYs, incremental net monetary benefit (iNMB), intervention rankings, and proportion of interventions with a positive iNMB.
We identified 28 articles discussing 9 alternatives. Feasible alternatives were using patient preference (PP) data; equity weighting according to baseline utility, fair innings, or proportional QALY shortfall; and the equal value of life-years-gained approach. All alternatives affected the incremental QALY and iNMB outcomes, rankings, and proportion of interventions with a positive iNMB. The PP alternative had the largest and most consistent impact. The PP impact on the proportion of interventions with a positive iNMB, was in the negative direction.
Our work is the first comprehensive evaluation of proposed alternatives to the conventional QALY. We found robust literature but few options that were feasible to be implemented in current healthcare decision-making processes.
质量调整生命年(QALY)一直备受争议,但替代评估方法尚未得到全面评估。我们的目标是确定替代方法,通过实施可行性对其进行特征描述,并评估在为 Institute for Clinical and Economic Review 报告开发的成本效益模型中实施可行方案的影响。
我们在 PubMed、EconLit、Web of Science 和 MEDLINE 中结合与 QALY、方法替代和成本效益相关的关键词进行文献综述。包括讨论传统 QALY 替代方法的文章。替代方法的特征包括类型、数据可用性、计算负担和总体实施可行性。可行替代方法的子集,即具有足够数据和方法的替代方法,与常见建模方法兼容,根据增量 QALY、增量净货币收益(iNMB)、干预措施排名以及具有正 iNMB 的干预措施的比例评估对增量 QALY 和 iNMB 结果、排名以及具有正 iNMB 的干预措施的比例的影响。
我们确定了 28 篇讨论 9 种替代方法的文章。可行的替代方法是使用患者偏好(PP)数据;根据基线效用、公平比赛或比例 QALY 短缺进行公平加权;以及等量生命年收益方法。所有替代方法都影响增量 QALY 和 iNMB 结果、排名以及具有正 iNMB 的干预措施的比例。PP 替代方案的影响最大且最一致。PP 对具有正 iNMB 的干预措施比例的影响为负面。
我们的工作是对传统 QALY 替代方法的首次全面评估。我们发现了可靠的文献,但在当前医疗保健决策过程中实施可行的替代方案很少。